Science Times: New cancer drugs are revolutionary. Why don’t more patients get them?
Plus: A.I. and religion, a SpaceX rocket test and TK
Science Times
October 2, 2026

Today, we look at how cancer patients may be missing out on a golden age of medicine, a test of the largest rocket ever built and Anthropic’s pursuit of morality in its A.I. Plus: the most read science article this week, and a reminder about the upcoming Nobel Prizes.

Why don’t more patients get new cancer drugs?

Mr. Ebers in a honey processing plant, holding up the lid of a barrel of crystallized honey.
Emily Elconin for The New York Times

Many patients could be helped by revolutionary new drugs that disable the genes fueling their tumors. But doctors are not sending their tumor cells to be tested or, even if they are, prescribing the drugs.

“We’re at a period where our molecular understanding is unprecedented,” said Dr. Paul Mischel, a physician scientist at Stanford. “But the infrastructure is really falling apart.”

“It’s a problem — it’s a big, big problem,” he added. “People should be really angry.”

Why are so few patients getting these groundbreaking treatments? Read the full story here.

Starship makes it to orbit

SpaceX, via Reuters

SpaceX’s Starship finally circled Earth earlier this week, a key milestone toward Elon Musk’s dreams of eventually sending people to Mars, as well as NASA’s plans to send astronauts back to the moon. (It had to return from space early, after less than two orbits instead of the planned six, because of engine problems that occurred during liftoff.)

Starship is the largest and most powerful rocket ever built. The design aims to be fully reusable; eventually both stages will return to the launch site to be caught by giant mechanical arms. If SpaceX pulls off this vision, Starship would revolutionize the space industry, enabling launches of bigger, heavier satellites and other cargo at lower costs.

Read the full story here.

IN THE NEWS

Cornell’s Jane Doe Said She Was Given Ketamine. Here’s How the Drug Works.

Ketamine is a short-acting anesthetic that can have hallucinogenic effects. It is becoming more easily available, and some experts fear misuse is increasing.

By Andrew Jacobs

Two hands hold small plastic bags of white crystals.

How Did Christa Pike Survive Two Lethal Injections of Pentobarbital?

A catheter carrying the drug may not have delivered the doses to Ms. Pike’s bloodstream, experts said. The drug itself may have been degraded.

By Benjamin Mueller and Shaila Dewan

An ambulance with bright lights turns onto a road at night, followed by two white vehicles.

Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working

Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.

By Gina Kolata

Ben Sasse speaks into a microphone while seated at a desk in a room with a large American flag and a white marble wall.

The quest for humanlike A.I.

The New York Times

Elizabeth Dias, our national religion correspondent, and Cade Metz, one of our technology reporters, discuss Anthropic’s approach to instilling morality into Claude — which has involved consultations with religious leaders, including ones at the Vatican — and why it’s raising questions.

Watch the full video here.

We hope you’ve enjoyed this newsletter, which is made possible through subscriber support. Subscribe to The New York Times.

Get stories that capture the wonders of nature, the cosmos and the human body.

Were you forwarded this newsletter? Sign up for Science Times.

Get stories that capture the wonders of nature, the cosmos and the human body.

Get it in your inbox.

TRENDING

Our most read story of the week

Article Image

Sophi Miyoko Gullbrants

Therapeutic Window

What if A.D.H.D. isn’t about attention at all? →

Next week: the Nobels

The Nobel Prizes are awarded every year in early October. Follow along! The Science desk will be covering the:

  • Nobel Prize in Physiology or Medicine on Monday
  • Nobel Prize in Physics on Tuesday
  • Nobel Prize in Chemistry on Wednesday

Thanks for joining us this week! Let us know how we’re doing at sciencenewsletter@nytimes.com.

If you received this newsletter from someone else, subscribe here.

Need help? Review our newsletter help page or contact us for assistance.

You received this email because you signed up for Science Times from The New York Times.

To stop receiving Science Times, unsubscribe. To opt out of other promotional emails from The Times, including those regarding The Athletic, manage your email settings.

Subscribe to The Times

Connect with us on:

facebookxwhatsapp

Change Your EmailPrivacy PolicyContact UsCalifornia Notices

Zeta LogoAdChoices Logo

The New York Times Company. 620 Eighth Avenue New York, NY 10018